Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
Latest Information Update: 05 Mar 2024
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- Acronyms PSMA PreRP
- 27 Jan 2024 Results (n=277; From December 2015 to December 2019) comparing the prognostic value of presurgical PSMA-PET and pelvic lymph nodes invasion (pN1) for biochemical recurrence (BCR) free-survival (FS) in patients with intermediate-risk to high-risk prostate cancer (PCa) treated with radical prostatectomy (RP) and pelvic lymph node dissection from NCT03368547, NCT02611882, NCT02919111 trials, presented at the 2024 Genitourinary Cancers Symposium.
- 07 Jun 2022 Results of post-hoc follow-up study from (n = 764; NCT03368547, NCT02611882, NCT02919111) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results determining the accuracy of 68Ga-PSMA-11 PET for the detection of pelvic nodal metastases (N1) compared to histopathology at time of radical prostatectomy (NCT03368547, NCT02611882, NCT02919111) presented at the 56th Annual Meeting of the American Society of Clinical Oncology